FDA Awards Grant for Phase 2 Trial to Deliver Sustainable LCA Treatment

Applied Genetic Technologies Corporation (Gainesville, FL) announced that it has received a $1 million grant from the FDA through its Orphan Drugs Program to fund a phase 2 human clinical trial evaluating the safety and efficacy of a treatment for Leber congenital amaurosis, according to a company news release. The tr...

Full Story →